porno
Monday, December 11, 2017
 Sheffield Bio-Science and Foremost Farms USA® to Expand Pharmaceutical Lactose Production  

Sheffield Bio-Science and Foremost Farms USA today announced a long-term manufacturing agreement that includes a joint investment to expand production of pharmaceutical lactose at Foremost Farms’ Rothschild, Wis., plant. Recognized individually as market leaders, this agreement further strengthens the combined force as the leading global supplier of direct compression lactose, and other oral solid dose excipients.

Foremost Farms, headquartered in Baraboo, Wisconsin, and Sheffield Bio-Science, headquartered in Beloit, Wisconsin, part of Kerry Group, initially began a partnership in 2007 in which Sheffield managed the sales, marketing and technical support of Foremost Farms’ pharmaceutical-grade lactose products. The lactose is sold internationally under the Foremostâ and Fast Floâ trademarks.

“This strategic alliance positions us well for providing customers with unsurpassed product value, enhanced opportunities for supply chain consolidation, and new technology innovation,” stated Edmond Scanlon, president of Sheffield Bio-Science.

“We believe this agreement is a natural extension for both Foremost Farms and Sheffield,” said Doug Wilke, vice president-marketing and technology, Foremost Farms USA. “By working together, we can focus on the manufacturing and marketing strengths of each partner while providing a sustainable supply that positions us as the leading lactose provider in the world.”

The agreement, which extends through 2019, has Sheffield continuing its responsibility for the sales, marketing and technical support of the Foremost lactose products for pharmaceutical applications. Both companies will make an investment to add anhydrous drying capacity at Foremost Farms’ Rothschild plant. Building modifications and equipment installation will begin immediately.

Together, the companies provide customers with greater access to the industry’s most extensive technologies, including anhydrous, spray dried, monohydrate, and inhalation grades of lactose. In addition, the alliance will provide customers with greater supply continuity and sustainability as the two companies leverage the Foremost Farms manufacturing facility as an alternative production site for the Sheffield anhydrous lactose products.

A global technical service platform encompasses established and new technologies for developing oral solid dosages as well as fermentation and biotechnology expertise. The combined business is uniquely positioned to collaborate directly with pharmaceutical formulators in the development of new drugs and delivery systems.

For more press information, please contact Jim Egan at Sheffield Bio-Science at 608-363-3086 or email jim.egan@kerry.com or Laura Mihm at Foremost Farms USA at 608-355-8798 or 608-963-7245 or email laura.mihm@foremostfarms.com. Visit  their companies online at www.sheffield-products.com and www.foremostfarms.com.

Source: Foremost Farms Press Release

 


Posted on Monday, December 28, 2009 (Archive on Monday, January 04, 2010)
Posted by bsutton@adpi.org  Contributed by bsutton@adpi.org
Return